Home / Stocks / ACN

Accenture (ACN, IT Consulting & Other Services) Stock Valuation & Fair Value Favorable on our tests

Accenture (ACN, IT Consulting & Other Services) trades at a blended P/E of 14.2, about 33% below its historical normal valuation, with a forward growth estimate of 8.1% and a PEG of 1.75. Analysts' one-year estimates have been hit 100% of the time. Priced at its historical normal P/E of 21.1 on the same blended earnings, the 2026-10-02 close of $198.90 corresponds to about $295 a share. This is a valuation reference, not a price target.

Blended P/E
14.2
Normal P/E
21.1
PEG
1.75
Fwd growth
8.1%
Div yield
3.4%
RSI (14)
63.2
Neutral
Technical context
  • Price $208.36 at the 2026-10-08 close, 10.2% above the 20-day average ($189.00) and 13.7% above the 50-day ($183.18).
  • RSI (14) at 63.2.
  • 52-week range $122.96 to $282.71: the price is 26.3% below the high and 69.5% above the low.
  • At its last earnings report the options market priced an 8.7% move.

The Street vs SeerForecast

Wall Street's mean price target for ACN is $221.36 across 24 analysts, 6.2% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: favorable on our tests. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been favorable on our tests since 2026-06-03.

Blended P/E and rating by weekBlended P/E moved from 13.1 to 14.2 between 2026-06-03 and 2026-10-02, against a normal P/E of 21.3, with 0 rating changes over 37 recorded weeks.2026-06-03: P/E 13.1, Favorable on our tests, recalculated for the week of 2026-06-032026-06-10: P/E 13.1, Favorable on our tests, recalculated for the week of 2026-06-102026-06-12: P/E 13.1, Favorable on our tests, recalculated for the week of 2026-06-142026-06-16: P/E 13.1, Favorable on our tests, recalculated for the week of 2026-06-162026-06-18: P/E 13.1, Favorable on our tests, recalculated for the week of 2026-06-212026-07-02: P/E 9.6, Favorable on our tests, recalculated for the week of 2026-07-022026-07-06: P/E 10.0, Favorable on our tests, recalculated for the week of 2026-07-062026-07-09: P/E 10.0, Favorable on our tests, recalculated for the week of 2026-07-092026-07-10: P/E 9.8, Favorable on our tests, recalculated for the week of 2026-07-122026-07-13: P/E 9.8, Favorable on our tests, recalculated for the week of 2026-07-132026-07-14: P/E 9.8, Favorable on our tests, recalculated for the week of 2026-07-142026-07-20: P/E 10.4, Favorable on our tests, recalculated for the week of 2026-07-202026-07-22: P/E 10.4, Favorable on our tests, recalculated for the week of 2026-07-222026-07-24: P/E 10.7, Favorable on our tests, recalculated for the week of 2026-07-252026-07-27: P/E 10.7, Favorable on our tests, recalculated for the week of 2026-07-272026-07-31: P/E 11.8, Favorable on our tests, recalculated for the week of 2026-07-312026-07-31: P/E 12.0, Favorable on our tests, recorded live 2026-08-032026-08-07: P/E 12.4, Favorable on our tests, recalculated for the week of 2026-08-072026-08-07: P/E 12.7, Favorable on our tests, recorded live 2026-08-102026-08-14: P/E 12.9, Favorable on our tests, recalculated for the week of 2026-08-142026-08-14: P/E 12.8, Favorable on our tests, recorded live 2026-08-172026-08-21: P/E 13.1, Favorable on our tests, recalculated for the week of 2026-08-212026-08-21: P/E 13.4, Favorable on our tests, recorded live 2026-08-242026-08-27: P/E 13.4, Favorable on our tests, recalculated for the week of 2026-08-272026-08-28: P/E 13.5, Favorable on our tests, recalculated for the week of 2026-08-282026-08-28: P/E 13.7, Favorable on our tests, recalculated for the week of 2026-08-302026-08-28: P/E 13.7, Favorable on our tests, recorded live 2026-08-312026-09-04: P/E 13.5, Favorable on our tests, recalculated for the week of 2026-09-052026-09-04: P/E 13.5, Favorable on our tests, recorded live 2026-09-072026-09-11: P/E 13.2, Favorable on our tests, recalculated for the week of 2026-09-122026-09-11: P/E 13.2, Favorable on our tests, recorded live 2026-09-142026-09-18: P/E 13.0, Favorable on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 13.0, Favorable on our tests, recorded live 2026-09-212026-09-25: P/E 12.7, Favorable on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 12.7, Favorable on our tests, recorded live 2026-09-282026-10-02: P/E 14.2, Favorable on our tests, recalculated for the week of 2026-10-032026-10-02: P/E 14.2, Favorable on our tests, recorded live 2026-10-0510.015.020.0Jun 3Jul 3Aug 2Sep 2Oct 2Normal P/E 21.3
Favorable on our tests

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 13.1-39%Favorable on our tests (recalculated)
2026-07-02P/E 9.6-55%Favorable on our tests (recalculated)
2026-10-03P/E 14.2-33%Favorable on our tests (recalculated)
2026-10-05P/E 14.2-33%Favorable on our tests ← now
Show all 37 weeks
WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 13.1-39%Favorable on our tests (recalculated)
2026-06-10P/E 13.1-39%Favorable on our tests (recalculated)
2026-06-14P/E 13.1-39%Favorable on our tests (recalculated)
2026-06-16P/E 13.1-39%Favorable on our tests (recalculated)
2026-06-21P/E 13.1-39%Favorable on our tests (recalculated)
2026-07-02P/E 9.6-55%Favorable on our tests (recalculated)
2026-07-06P/E 10.0-53%Favorable on our tests (recalculated)
2026-07-09P/E 10.0-53%Favorable on our tests (recalculated)
2026-07-12P/E 9.8-54%Favorable on our tests (recalculated)
2026-07-13P/E 9.8-54%Favorable on our tests (recalculated)
2026-07-14P/E 9.8-54%Favorable on our tests (recalculated)
2026-07-20P/E 10.4-51%Favorable on our tests (recalculated)
2026-07-22P/E 10.4-51%Favorable on our tests (recalculated)
2026-07-25P/E 10.7-50%Favorable on our tests (recalculated)
2026-07-27P/E 10.7-50%Favorable on our tests (recalculated)
2026-07-31P/E 11.8-44%Favorable on our tests (recalculated)
2026-08-03P/E 12.0-44%Favorable on our tests
2026-08-07P/E 12.4-42%Favorable on our tests (recalculated)
2026-08-10P/E 12.7-40%Favorable on our tests
2026-08-14P/E 12.9-39%Favorable on our tests (recalculated)
2026-08-17P/E 12.8-40%Favorable on our tests
2026-08-21P/E 13.1-39%Favorable on our tests (recalculated)
2026-08-24P/E 13.4-37%Favorable on our tests
2026-08-27P/E 13.4-37%Favorable on our tests (recalculated)
2026-08-28P/E 13.5-37%Favorable on our tests (recalculated)
2026-08-30P/E 13.7-36%Favorable on our tests (recalculated)
2026-08-31P/E 13.7-36%Favorable on our tests
2026-09-05P/E 13.5-37%Favorable on our tests (recalculated)
2026-09-07P/E 13.5-37%Favorable on our tests
2026-09-12P/E 13.2-38%Favorable on our tests (recalculated)
2026-09-14P/E 13.2-38%Favorable on our tests
2026-09-19P/E 13.0-39%Favorable on our tests (recalculated)
2026-09-21P/E 13.0-39%Favorable on our tests
2026-09-26P/E 12.7-41%Favorable on our tests (recalculated)
2026-09-28P/E 12.7-41%Favorable on our tests
2026-10-03P/E 14.2-33%Favorable on our tests (recalculated)
2026-10-05P/E 14.2-33%Favorable on our tests ← now

Earnings moves: ACN moved more than the options market implied in 1 of 1 recent tracked reports.

Frequently asked questions

Is Accenture stock overvalued?

At a blended P/E of 14.2 versus its historical normal P/E of 21.1, Accenture trades about 33% below its typical valuation, with a PEG of 1.75 on 8.1% forward growth. tickerseer currently rates it favorable on our tests.

What is Accenture's fair value and PEG?

Accenture trades at a blended P/E of 14.2 against a historical normal P/E of 21.1, a PEG of 1.75, and a forward growth estimate of 8.1%. Priced at its historical normal P/E of 21.1 on the same blended earnings, the 2026-10-02 close of $198.90 corresponds to about $295 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Accenture changed?

tickerseer's rating has been favorable on our tests since 2026-06-03.

What is the analyst price target for Accenture?

The mean Wall Street price target for Accenture is $221.36 across 24 analysts, 6.2% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: IT Consulting & Other Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.